| 发明名称 |
Pharmaceutical formulation |
| 摘要 |
The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis. |
| 申请公布号 |
US8772303(B2) |
申请公布日期 |
2014.07.08 |
| 申请号 |
US200912478934 |
申请日期 |
2009.06.05 |
| 申请人 |
Glaxo Group Limited |
发明人 |
Van Schie Dirk Marinus Johannes |
| 分类号 |
A61K31/513 |
主分类号 |
A61K31/513 |
| 代理机构 |
|
代理人 |
Sauermelch Loretta J.;Scrivner Alan X. |
| 主权项 |
1. A pharmaceutical formulation comprising a core which includes a pharmaceutically active ingredient which is 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one and a casing which comprises an enteric polymer. |
| 地址 |
Brentford, Middlesex GB |
